Abstract:Background & Aim Acute respiratory distress syndrome (ARDS) is a severe hypoxemic respiratory failure characterized by recognizable diffuse alveolar damage and lung injury, with high mortality. Unfortunately, the current treatment for ARDS is mainly supportive. Although preclinical models of ARDS have demonstrated that mesenchymal stromal cells (MSCs) protects the lung against injury, their mechanisms are not yet fully understood. Accumulating evidence has indicated that the cholinergic anti-inflammatory pathway (CAP) is involved in controlling inflammation in various inflammatory situations, we then investigate whether CAP play the critical role in the therapeutic effect of MSC to mitigate ARDS. Methods, Results & Conclusion Lipopolysaccharide (LPS)-induced lung injury model was induced in C57BL/6J mice by nasal drip, followed by an intravenous injection of MSCs or saline 6 hours later. Lung tissue was profiled in three groups of MSC or saline treatment in lung-injury mice and sham in wild type mice. AR-R1779HCl and Methyllycaconitine citrate were used to specifically activate or block α7nAChR respectively. Indomethacin and MF63, inhibiting PTGES and PGES-1 respectively, were used to restrain MSC producing PGE2. After MSC infusions to LPS-induce lung injury mice, the pulmonary vascular permeability were improved and inflammatory cell infiltration were reduced within 6 hours. The expression profile sequencing of lung tissue showed that ChAT, VAChT and other cholinergic system-related genes were significantly increased after MSC treatment. When specifically blocking the acetylcholine (ACh) receptor 7nAChR, the therapeutic effects of MSC significantly reduced, suggesting that the cholinergic anti-inflammatory pathway (CAP) may play an important role in MSC treating ARDS. Moreover, prostaglandin E2 (PGE2) produced by MSC, likely to increase ChAT synthesis of cholinergic nerves. These results supported that MSCs inhibit severe inflammatory response of ARDS through activating CAP-mediated anti-inflammatory regulation, partially through increasing the synthesis of acetylcholine via PGE2. In summary, we have revealed a previously unrecognized mechanism of MSC-mediated activation of the cholinergic anti-inflammatory pathway in alleviating ARDS-like syndrome, which provide evidences for clinical translation of MSC in patients with ARDS. Acute respiratory distress syndrome (ARDS) is a severe hypoxemic respiratory failure characterized by recognizable diffuse alveolar damage and lung injury, with high mortality. Unfortunately, the current treatment for ARDS is mainly supportive. Although preclinical models of ARDS have demonstrated that mesenchymal stromal cells (MSCs) protects the lung against injury, their mechanisms are not yet fully understood. Accumulating evidence has indicated that the cholinergic anti-inflammatory pathway (CAP) is involved in controlling inflammation in various inflammatory situations, we then investigate whether CAP play the critical role in the therapeutic effect of MSC to mitigate ARDS. Lipopolysaccharide (LPS)-induced lung injury model was induced in C57BL/6J mice by nasal drip, followed by an intravenous injection of MSCs or saline 6 hours later. Lung tissue was profiled in three groups of MSC or saline treatment in lung-injury mice and sham in wild type mice. AR-R1779HCl and Methyllycaconitine citrate were used to specifically activate or block α7nAChR respectively. Indomethacin and MF63, inhibiting PTGES and PGES-1 respectively, were used to restrain MSC producing PGE2.

YAP-regulated type II alveolar epithelial cell differentiation mediated by human umbilical cord-derived mesenchymal stem cells in acute respiratory distress syndrome

Early and Dose-Dependent Xenogeneic Mesenchymal Stem Cell Therapy Improved Outcomes in Acute Respiratory Distress Syndrome Rodent Through Ameliorating Inflammation, Oxidative Stress, and Immune Reaction

Reduction of Emphysema Severity by Human Umbilical Cord-Derived Mesenchymal Stem Cells in Mice

Abstract PR566

Treatment of Acute Respiratory Distress Syndrome with Allogeneic Adipose-Derived Mesenchymal Stem Cells: a Randomized, Placebo-Controlled Pilot Study.

Comparative Effects of Umbilical Cord- and Menstrual Blood-Derived MSCs in Repairing Acute Lung Injury

Mesenchymal Stem Cell Conditioned Medium Promotes Proliferation and Migration of Alveolar Epithelial Cells under Septic Conditions In Vitro via the JNK-P38 Signaling Pathway

Human Umbilical Cord Mesenchymal Stem Cells Promote Macrophage PD-L1 Expression and Attenuate Acute Lung Injury in Mice

Placental mesenchymal stem cells boost M2 alveolar over M1 bone marrow macrophages via IL-1β in Klebsiella-mediated acute respiratory distress syndrome

Mesenchymal stromal cells alleviate acute respiratory distress syndrome through the cholinergic anti-inflammatory pathway

Identification and Modulation of Microenvironment Is Crucial for Effective Mesenchymal Stromal Cell Therapy in Acute Lung Injury

Effects of different concentrations of mesenchymal stem cells treatment on LPS-induced acute respiratory distress syndrome rat model

Human amnion-derived mesenchymal stem cells attenuate acute lung injury in two different acute lung injury mice models

Umbilical cord mesenchymal stem cells overexpressing CXCR7 facilitate treatment of ARDS-associated pulmonary fibrosis via inhibition of Notch/Jag1 mediated by the Wnt/β-catenin pathway

Activation of Wnt/β-catenin signalling promotes mesenchymal stem cells to repair injured alveolar epithelium induced by lipopolysaccharide in mice

Role of DCLK1/Hippo pathway in type II alveolar epithelial cells differentiation in acute respiratory distress syndrome

Identification and Modulation of Microenvironment is Crucial for Effective MSC Therapy in Acute Lung Injury.

Mesenchymal Stromal Cells Alleviates Experimental Acute Respiratory Distress Syndrome Through the Cholinergic Anti-Inflammatory Pathway

The ARDS microenvironment enhances MSC-induced repair via VEGF in experimental acute lung inflammation

Retraction Note: Overexpressing P130/e2f4 in Mesenchymal Stem Cells Facilitates the Repair of Injured Alveolar Epithelial Cells in LPS-induced ARDS Mice

The Hepatocyte Growth Factor-Expressing Character is Required for Mesenchymal Stem Cells to Protect the Lung Injured by Lipopolysaccharide in Vivo